GSK and Chai Discovery AI-Powered Drug Discovery Collaboration
Drug giant GSK has partnered with Chai Discovery to access AI-powered protein folding models following successful lab tests.
GSK has signed a new agreement with AI-focused biotechnology company Chai Discovery to gain access to protein folding and design models.
Details of the Agreement
GSK has reached an agreement to gain access to Chai Discovery's AI-driven protein folding and design models. With this step, the company joined Chai's customer portfolio.
Laboratory Tests
Internal wet lab tests conducted by GSK confirmed that designs generated by the AI models bound to all tested targets. The strong binding affinities achieved drew attention.
Industry Developments
San Francisco-based Chai Discovery has emerged to the forefront in AI-powered drug discovery by establishing partnerships with major pharmaceutical companies such as Bristol Myers Squibb, Eli Lilly, Novartis, and Pfizer.